News

C4 Therapeutics, Inc. has announced a new collaboration agreement with Roche to advance research in a promising cancer treatment approach known as degrader-antibody conjugates (DACs).…
Read More...

AC Immune SA has strengthened its long-standing partnership with Eli Lilly and Company through an amendment to their 2018 collaboration agreement, advancing efforts to develop novel…
Read More...

Nxera Pharma Co., Ltd. has reached a key development milestone in its ongoing collaboration with Eli Lilly and Company, advancing joint efforts to develop new treatments for diabetes…
Read More...

Sidewinder Therapeutics has raised $137 million in an oversubscribed Series B financing round, signaling strong investor confidence in its next-generation cancer treatment platform…
Read More...

Jeito Capital has successfully closed its second fund, Jeito II, raising $1.2 billion and exceeding its initial target, in a move that underscores growing investor confidence in…
Read More...

RoosterBio, Inc. has entered into an exclusive distribution agreement with MineBio Life Sciences Limited to expand access to advanced cell therapy manufacturing solutions across China,…
Read More...

Gilead Sciences, Inc. has announced a definitive agreement to acquire Tubulis GmbH, a clinical-stage biotech firm specializing in next-generation antibody-drug conjugates (ADCs). The…
Read More...

Halozyme Therapeutics, Inc. has announced a new global collaboration and licensing agreement with Vertex Pharmaceuticals Incorporated aimed at advancing innovative drug delivery…
Read More...

Sidewinder Therapeutics has announced the successful close of an oversubscribed $137 million Series B financing round, marking a significant milestone for the emerging biopharmaceutical…
Read More...

Shionogi & Co., Ltd. has secured a major U.S. government contract to expand the development and supply of its antibiotic Fetroja, reinforcing efforts to combat drug-resistant…
Read More...

Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. to advance the development of next-generation antisense therapeutics targeting multiple…
Read More...

Neurocrine Biosciences, Inc. has entered into a definitive agreement to acquire Soleno Therapeutics, Inc. in an all-cash transaction valued at approximately $2.9 billion, marking a…
Read More...

Apnimed, Inc. has secured a senior secured credit facility of up to $150 million from funds managed by HealthCare Royalty Partners, providing a major financial boost as the company…
Read More...

Akari Therapeutics Plc has announced a strategic partnership with WuXi XDC to accelerate the development of its next-generation antibody-drug conjugate (ADC) technology, marking a…
Read More...

Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with additional…
Read More...

Teva Pharmaceutical Industries has announced a series of significant milestones in its biosimilars portfolio, underscoring progress in its broader “Pivot to Growth” strategy and…
Read More...

Symeres has entered into a strategic collaboration with Ambagon Therapeutics to explore a promising new class of small molecules known as molecular glues for the treatment of colorectal…
Read More...

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, marking a significant step in Biogen’s strategy to…
Read More...

Biogen Inc. has announced that the U.S. Food and Drug Administration has approved a high-dose regimen of its therapy SPINRAZA for the treatment of spinal muscular atrophy (SMA), marking…
Read More...

Otsuka Pharmaceutical has announced plans to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, strengthening its presence in the neuropsychiatric treatment space…
Read More...